Biotechnology
Double-blind period completes! Primary endpoint analysis of phase 3 clinical trial to be conducted for China's first hormone replacement treatment targeting hypoparathyroidism
Submission of NDA to the NMPA is planned within 2023 at the earliest SHANGHAI, Jan. 6, 2023 /PRNewswire/ -- VISEN Pharmaceuticals, an innovative biopharmaceutical company focused on endocrine diseases, announced today that it has completed the double-blind period of PaTHway China Trial, a phase 3...
2023-01-06 18:00
1485
SK Biopharmaceuticals CEO Donghoon Lee Buys 3,000 Shares of Company Stock
- CEO shows commitment and confidence in the company's future through share purchase PANGYO, South Korea, Jan. 5, 2023 /PRNewswire/ -- SK Biopharmaceuticals, an innovative global pharmaceutical company, today announced that Mr.Donghoon Lee, the Chief Executive Officer and President of SK Biophar...
2023-01-06 09:10
1348
Kira to Present at the 41st Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. and SUZHOU, China, Jan. 5, 2023 /PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement therapies to treat immune-mediated diseases, today announced that Frederick Beddingfield M.D., Ph.D., Chief Executive Officer, will present a...
2023-01-05 23:30
2400
AMR Action Fund Announces Investment in BioVersys AG
Deal marks Fund's first investment in Europe and advances its mission of enabling the launch of two to four antimicrobials by 2030 BOSTON, Jan. 5, 2023 /PRNewswire/ -- The AMR Action Fund, the world's largest public-private partnership investing in biotech companies that are developing antimicr...
2023-01-05 20:00
7503
Shine-On Biomedical Co., Ltd. Accorded the International Innovation Awards 2022 for TROY CAR EXOs
SINGAPORE, Jan. 5, 2023 /PRNewswire/ -- Enterprise Asia is pleased to honor 39 remarkable innovations at the 6th International Innovation Awards (IIA) 2022. The awards took place inBangkok, Thailand following the International Innovation Summit 2022 which convened over 300 innovation experts, ind...
2023-01-05 18:20
2383
Oneness Biotech Co., Ltd.'s FESPIXON® Honored at the International Innovation Awards 2022
SINGAPORE, Jan. 5, 2023 /PRNewswire/ -- Enterprise Asia is pleased to honor 39 remarkable innovations at the 6th International Innovation Awards (IIA) 2022. The awards took place inBangkok, Thailand following the International Innovation Summit 2022 which convened over 300 innovation experts, ind...
2023-01-05 17:46
2560
Novogene Announces Deployment of Illumina NovaSeq™ X Plus and PacBio REVIO Sequencing Systems
SINGAPORE, Jan. 5, 2023 /PRNewswire/ -- Novogene
2023-01-05 17:00
2382
Aurisco cooperates with Cytiva to build its first Oligo FlexFactory for commercial production
* Located in Yangzhou of East China, Aurisco's new commercial manufacturing site is expected to produce 200 kilograms of oligonucleotides each year. * Through the cooperation with Cytiva, Aurisco will deliver more oligonucleotides to its global customers with better quality and efficiency. SH...
2023-01-05 14:36
1586
Duality Biologics Announces License Agreement of its Next-generation ADC platform with Adcendo
* Duality to grant license of DITAC (Duality Immune Toxin Antibody Conjugates) platform to Adcendo for its lead uPARAP ADC program * Duality to receive upfront payment, development, regulatory and commercial milestones, and tiered royalties * Collaboration based on synergies between Adcendo ...
2023-01-05 09:00
1185
Ascentage Pharma to Present at the 41st Annual J.P. Morgan Healthcare Conference
SUZHOU, China and ROCKVILLE, Md., Jan. 4, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that its Chairman and CEO, Dr.Dajun Yang, has accep...
2023-01-05 09:00
2198
WuXi Biologics and GSK Enter into License Agreement on Multiple Novel Bi- & Multi-specific T Cell Engagers
* WuXi Biologics will provide an exclusive license to GSK for one preclinical bi-specific T cell engaging (TCE) antibody and the option of three additional bi-/multi-specific TCE antibodies developed using WuXi Biologics' proprietary technology platforms * WuXi Biologics will receive an upfro...
2023-01-05 08:30
3655
Innovent Announces NMPA's Breakthrough Therapy Designation for IBI351 (KRAS G12C Inhibitor) as Monotherapy for Previous Treated Advanced Non-small Cell Lung Cancer
ROCKVILLE, Md. and SUZHOU, China, Jan. 5, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and...
2023-01-05 08:00
3451
DiscGenics to Present at 41st Annual J.P. Morgan Healthcare Conference
SALT LAKE CITY, Jan. 5, 2023 /PRNewswire/ -- DiscGenics, Inc., a privately held, clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that it w...
2023-01-05 08:00
1861
Innovent to Present at 41st Annual J.P. Morgan Healthcare Conference
ROCKVILLE, Md. and SUZHOU, China, Jan. 5, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", "the Company") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, o...
2023-01-05 00:00
2323
Innovent to Present at 41st Annual J.P. Morgan Healthcare Conference
ROCKVILLE, Md. and SUZHOU, China, Jan. 4, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", "the Company") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, o...
2023-01-05 00:00
2254
Hummingbird Bioscience and Synaffix Enter License Agreement to Develop a Next Generation Antibody Drug Conjugate (ADC) Program
* Synaffix to provide Hummingbird Bioscience access to proprietary ADC technologies * Synaffix to receive up to $150m in upfront and milestone payments plus royalties SAN FRANCISCO, HOUSTON and SINGAPORE, Jan. 4, 2023 /PRNewswire/ -- Synaffix B.V. (Synaffix), a biotechnology company focused ...
2023-01-04 21:00
2277
OnCusp Therapeutics Announces Appointment of Robert Forrester and Chau Khuong to Board of Directors
NEW YORK, Jan. 4, 2023 /PRNewswire/ -- OnCusp Therapeutics, a global biotechnology company with deep translational and clinical development expertise in oncology therapeutics, today announced the appointment of serial entrepreneurRobert Forrester and venture capitalist Chau Khuong as independent ...
2023-01-04 21:00
1859
Transcenta Received IND Clearance from NMPA for Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors
SUZHOU, China, Jan. 4, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics,announces that TST003, its first...
2023-01-04 08:00
2234
Alterity Therapeutics to Participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum
MELBOURNE, Australia and SAN FRANCISCO, Jan. 3, 2023 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced thatDavid Stamler, M.D., ...
2023-01-03 23:25
1440
Burning Rock Received FDA Breakthrough Device Designation for its OverC™ Multi-Cancer Detection Blood Test
IRVINE, Calif., Jan. 3, 2023 /PRNewswire/ -- Burning Rock (NASDAQ/LSE: BNR), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that its OverC™ Multi-Cancer Detection Blood Test (MCDBT) has been granted Breakthro...
2023-01-03 22:24
861
Week's Top Stories
Most Reposted
LINKDOOD Breaks Language Barriers, Ushering a New Era for Cross-Border Romance
[Picked up by 326 media titles]
2024-04-29 06:00
Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
[Picked up by 291 media titles]
2024-04-30 10:11
Puyuan Fashion Resort 2024: A Grand Unveiling of Global Trends and Local Heritage
[Picked up by 269 media titles]
2024-04-28 09:39
Chinese new energy industry contributes to global green, low-carbon transition
[Picked up by 249 media titles]
2024-04-30 15:13New International Land-Sea Trade Corridor achieves rapid development
[Picked up by 246 media titles]
2024-04-28 10:24Most Read
Scienjoy Holding Corporation Reports Fiscal Year 2023 Financial Results
2024-04-27 04:30
2931
